Cargando…

Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole

BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that has been implicated as the leading cause of antibiotic-associated diarrhea. Metronidazole is currently the first-line treatment for mild to moderate C. difficile infections. Our laboratory isolated a strain of C. diffici...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Patrick M., Lynch, Tarah, McCorrister, Stuart, Kibsey, Pamela, Miller, Mark, Gravel, Denise, Westmacott, Garrett R., Mulvey, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882210/
https://www.ncbi.nlm.nih.gov/pubmed/24400070
http://dx.doi.org/10.1371/journal.pone.0082622
_version_ 1782298323024084992
author Chong, Patrick M.
Lynch, Tarah
McCorrister, Stuart
Kibsey, Pamela
Miller, Mark
Gravel, Denise
Westmacott, Garrett R.
Mulvey, Michael R.
author_facet Chong, Patrick M.
Lynch, Tarah
McCorrister, Stuart
Kibsey, Pamela
Miller, Mark
Gravel, Denise
Westmacott, Garrett R.
Mulvey, Michael R.
author_sort Chong, Patrick M.
collection PubMed
description BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that has been implicated as the leading cause of antibiotic-associated diarrhea. Metronidazole is currently the first-line treatment for mild to moderate C. difficile infections. Our laboratory isolated a strain of C. difficile with a stable resistance phenotype to metronidazole. A shotgun proteomics approach was used to compare differences in the proteomes of metronidazole-resistant and -susceptible isolates. METHODOLOGY/PRINCIPAL FINDINGS: NAP1 C. difficile strains CD26A54_R (Met-resistant), CD26A54_S (reduced- susceptibility), and VLOO13 (Met-susceptible) were grown to mid-log phase, and spiked with metronidazole at concentrations 2 doubling dilutions below the MIC. Peptides from each sample were labeled with iTRAQ and subjected to 2D-LC-MS/MS analysis. In the absence of metronidazole, higher expression was observed of some proteins in C. difficile strains CD26A54_S and CD26A54_R that may be involved with reduced susceptibility or resistance to metronidazole, including DNA repair proteins, putative nitroreductases, and the ferric uptake regulator (Fur). After treatment with metronidazole, moderate increases were seen in the expression of stress-related proteins in all strains. A moderate increase was also observed in the expression of the DNA repair protein RecA in CD26A54_R. CONCLUSIONS/SIGNIFICANCE: This study provided an in-depth proteomic analysis of a stable, metronidazole-resistant C. difficile isolate. The results suggested that a multi-factorial response may be associated with high level metronidazole-resistance in C. difficile, including the possible roles of altered iron metabolism and/or DNA repair.
format Online
Article
Text
id pubmed-3882210
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38822102014-01-07 Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole Chong, Patrick M. Lynch, Tarah McCorrister, Stuart Kibsey, Pamela Miller, Mark Gravel, Denise Westmacott, Garrett R. Mulvey, Michael R. PLoS One Research Article BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that has been implicated as the leading cause of antibiotic-associated diarrhea. Metronidazole is currently the first-line treatment for mild to moderate C. difficile infections. Our laboratory isolated a strain of C. difficile with a stable resistance phenotype to metronidazole. A shotgun proteomics approach was used to compare differences in the proteomes of metronidazole-resistant and -susceptible isolates. METHODOLOGY/PRINCIPAL FINDINGS: NAP1 C. difficile strains CD26A54_R (Met-resistant), CD26A54_S (reduced- susceptibility), and VLOO13 (Met-susceptible) were grown to mid-log phase, and spiked with metronidazole at concentrations 2 doubling dilutions below the MIC. Peptides from each sample were labeled with iTRAQ and subjected to 2D-LC-MS/MS analysis. In the absence of metronidazole, higher expression was observed of some proteins in C. difficile strains CD26A54_S and CD26A54_R that may be involved with reduced susceptibility or resistance to metronidazole, including DNA repair proteins, putative nitroreductases, and the ferric uptake regulator (Fur). After treatment with metronidazole, moderate increases were seen in the expression of stress-related proteins in all strains. A moderate increase was also observed in the expression of the DNA repair protein RecA in CD26A54_R. CONCLUSIONS/SIGNIFICANCE: This study provided an in-depth proteomic analysis of a stable, metronidazole-resistant C. difficile isolate. The results suggested that a multi-factorial response may be associated with high level metronidazole-resistance in C. difficile, including the possible roles of altered iron metabolism and/or DNA repair. Public Library of Science 2014-01-06 /pmc/articles/PMC3882210/ /pubmed/24400070 http://dx.doi.org/10.1371/journal.pone.0082622 Text en © 2014 Chong et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Chong, Patrick M.
Lynch, Tarah
McCorrister, Stuart
Kibsey, Pamela
Miller, Mark
Gravel, Denise
Westmacott, Garrett R.
Mulvey, Michael R.
Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
title Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
title_full Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
title_fullStr Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
title_full_unstemmed Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
title_short Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
title_sort proteomic analysis of a nap1 clostridium difficile clinical isolate resistant to metronidazole
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882210/
https://www.ncbi.nlm.nih.gov/pubmed/24400070
http://dx.doi.org/10.1371/journal.pone.0082622
work_keys_str_mv AT chongpatrickm proteomicanalysisofanap1clostridiumdifficileclinicalisolateresistanttometronidazole
AT lynchtarah proteomicanalysisofanap1clostridiumdifficileclinicalisolateresistanttometronidazole
AT mccorristerstuart proteomicanalysisofanap1clostridiumdifficileclinicalisolateresistanttometronidazole
AT kibseypamela proteomicanalysisofanap1clostridiumdifficileclinicalisolateresistanttometronidazole
AT millermark proteomicanalysisofanap1clostridiumdifficileclinicalisolateresistanttometronidazole
AT graveldenise proteomicanalysisofanap1clostridiumdifficileclinicalisolateresistanttometronidazole
AT westmacottgarrettr proteomicanalysisofanap1clostridiumdifficileclinicalisolateresistanttometronidazole
AT mulveymichaelr proteomicanalysisofanap1clostridiumdifficileclinicalisolateresistanttometronidazole
AT proteomicanalysisofanap1clostridiumdifficileclinicalisolateresistanttometronidazole